REGN
Regeneron PharmaceuticalsRegeneron Pharmaceuticals is a biotechnology name in the health care sector. Over the past year it returned +21.7%, against +7.6% over three months and -13.9% over one. It sits 1.1% below its 200-day average, close enough that the trend is undecided. Annualized volatility of 32.8% is above the market's typical range.
Its worst peak-to-trough decline over the year was -25.9%, and it has traded a median $495M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.18 with the S&P 500 proxy, so it has been moving substantially on its own.
How REGN scores on all four profiles
Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.
Start a free 7-day trial| 1 day | -1.2% |
| 1 week | -3.4% |
| 1 month | -13.9% |
| 3 months | +7.6% |
| 6 months | -4.5% |
| 1 year | +21.7% |
| 12-1 momentum | +41.3% |
| Volatility (1y, annualized) | 32.8% |
| Max drawdown (1y) | -25.9% |
| Distance vs 200-day average | -1.1% |
| Return per unit of risk | 0.66 |
| Median daily dollar volume | $495M |
Get REGN when it shows up in a ranking
Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.
Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.